Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum Chemotherapy vs Capecitabine in Residual Triple-Negative Breast Cancer
NCT02445391Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Oct 2015
- Primary completion
- Apr 2021
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), carboplatin in triple-negative breast cancer (TNBC), sponsored by ECOG-ACRIN Cancer Research Group. Started Oct 2015; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02445391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445391.